Faculty profile

Aaron Schimmer

ResearcherHematology-OncologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Aaron Schimmer

Researcher

Hematology-Oncology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
9 publications in the last five years, latest in 2026.
Principal investigator on 12 research grants (11 CIHR, 1 NSERC), most recently in 2024.
Supervised 10 trainees who won CIHR awards, most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

134

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Leukemia Translational Research Mitochondria Metabolism Genomics Stem Cells Cell Biology Mitosis

Latest papers

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.
Current oncology (Toronto, Ont.) · 2026
What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
Clinical lymphoma, myeloma & leukemia · 2026
Extramedullary AML: Clinical and Molecular Features.
Cancers · 2026

All 36 publications

Latest funding

The role of Bcl-2 family proteins in T cell activation and activity against acute myeloid leukemia
CIHR · 2024 · Supervisor
$120,000
The IL23 Receptor (IL23R) regulates mitotic spindle formation and is a novel therapeutic target for AML
CIHR · 2024 · Nominated PI
$1,067,175
Interleukin 23 Receptor (IL-23R) is a Regulator of the Mitotic Spindle and Centrosomes and is Necessary for AML Viability
CIHR · 2023 · Supervisor
$105,000

All 32 grants and awards

36 publications.

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Eng DZS, Khadadah F, Perusini MA, Al-Shaibani E, Atenafu EG, Bankar A, Davidson M, Richard-Carpentier G, Maze D, Yee K, Schimmer A, Gupta V, Chan S, Kim DDH, Schuh A, Minden M, Sibai H

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33020127 PMID: 41744891

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Rajendra A, Smith E, Atenafu EG, Bankar A, Chan S, Davidson M, Gupta V, Minden MD, Perusini MA, Richard-Carpentier G, Schimmer A, Schuh AC, Sibai H, Yee K, Maze D

Clinical lymphoma, myeloma & leukemia2026

DOI: 10.1016/j.clml.2025.10.016 PMID: 41238480

Extramedullary AML: Clinical and Molecular Features.

Morgenstern Y, Andrews C, Atenafu EG, Chan S, Gupta V, Minden MD, Maze D, Schimmer A, Schuh A, Yee K, Sibai H

Cancers2026

DOI: 10.3390/cancers18091362 PMID: 42122157

Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort.

Wangulu C, Zhao D, Zhou Q, Wei C, Kumar R, Schimmer A, Chang H

Cancers2025

DOI: 10.3390/cancers17091405 PMID: 40361333

Identifying Risk Factors and Outcome for CNS Involvement in AML.

Seki JT, Daher-Reyes GS, Atenafu EG, Sibai J, Bankar A, Young T, Chan S, Yee K, Gupta V, Minden MD, Maze D, Schuh A, Schimmer A, Sibai H

Clinical lymphoma, myeloma & leukemia2025

DOI: 10.1016/j.clml.2025.06.010 PMID: 40744760

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.

Smith E, Atenafu EG, Bankar A, Chan S, Davidson M, Gupta V, Minden MD, Richard-Carpentier G, Schimmer A, Schuh AC, Sibai H, Yee K, Maze D

European journal of haematology2024

DOI: 10.1111/ejh.14283 PMID: 39113600

Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia.

Murphy T, Zou J, Arruda A, Wang TT, Zhao Z, Zheng Y, Gupta V, Maze D, McNamara C, Minden MD, Schimmer A, Sibai H, Yee K, Capo-Chichi JM, Stockley T, Schuh A, Bratman SV, Chan SM

Haematologica2024

DOI: 10.3324/haematol.2023.283510 PMID: 37345484

Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study

Munshi L, Dumas G, Rochwerg B, Shoukat F, Detsky M, Fergusson DA, Ferreyro BL, Heffernan P, Herridge M, Magder S

Intensive Care Medicine202459 citations

DOI: 10.1007/s00134-024-07349-z

Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.

Vasudevan Nampoothiri R, Tang K, Schuh A, Lam W, Maze D, Michelis FV, Chan S, Gupta V, Kim D, Kumar R, Lipton JH, Mattsson J, Minden M, Schimmer A, Sibai H, Viswabandya A, Yee K, Murphy T, Law AD

European journal of haematology2023

DOI: 10.1111/ejh.13940 PMID: 36732677

Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Daher-Reyes G, Kim T, Novitzky-Basso I, Kim KH, Smith A, Stockley T, Capochichi JM, Al-Shaibani Z, Pasic I, Law A, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Schimmer A, McNamara C, Murphy T, Maze D, Gupta V, Sibai H, Chan S, Yee K, Minden M, Zhang Z, Schuh A, Kim DDH

Bone marrow transplantation2021

DOI: 10.1038/s41409-021-01255-4 PMID: 33767401

Something wrong or missing on this profile? Suggest a correction

Aaron Schimmer

Research

Latest papers

Latest funding

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Extramedullary AML: Clinical and Molecular Features.

Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort.

Identifying Risk Factors and Outcome for CNS Involvement in AML.

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.

Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia.

Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study

Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.

Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Frequent collaborators

Steven Chan

Gary Rodin

Camilla Zimmermann

Mark Minden

Christopher Lo

Fei-Fei Liu

Rinat Nissim

Rajat Kumar

Tracy Stockley

Jonas Mattsson

Brian Raught

Zhaolei Zhang

Justyna Bartoszko

Sheldon Magder

Sangeeta Mehta

Margaret Herridge

Yigal Dror

Tony Panzarella

Adam Smith

Nicholas Mitsakakis

Joseph Beyene

Bram Rochwerg

Gregory Pond